Literature DB >> 22361690

Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders.

Nicholas Parziale1, Susan C Kovacs, Christine B Thomas, Jayashri Srinivasan.   

Abstract

We report a case of dermatomyositis associated with rheumatoid arthritis, Hashimoto thyroiditis, and diabetes mellitus responsive only to combination of rituximab with mycophenolate. A 42-year-old woman presented with proximal muscle weakness, myalgias, fever, night sweats, and shortness of breath. Creatinine kinase was 8155 IU/L, and muscle biopsy was diagnostic of dermatomyositis. She was started on glucocorticoids; her systemic symptoms improved, but her muscle weakness persisted. She was serially treated with intravenous immunoglobulin, azathioprine, and mycophenolate mofetil without improvement in her weakness. She responded dramatically to combination therapy with rituximab and mycophenolate, with improvement in strength and normalization of creatinine kinase. She has been well controlled on rituximab infusion every 6 months and maintenance mycophenolate mofetil.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22361690     DOI: 10.1097/CND.0b013e318221259d

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  2 in total

Review 1.  Cutaneous dermatomyositis in the era of biologicals.

Authors:  Natalie A Wright; Ruth Ann Vleugels; Jeffrey P Callen
Journal:  Semin Immunopathol       Date:  2015-11-12       Impact factor: 9.623

2.  Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil.

Authors:  Mike Lin; Venessa Tsang; Janice Brewer; Roderick Clifton-Bligh; Matti L Gild
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.